Version 1
: Received: 11 September 2023 / Approved: 12 September 2023 / Online: 12 September 2023 (07:15:53 CEST)
How to cite:
Maes, A.; Gosselin, L.; Triquenot, A.; Darmoni, S.; Grosjean, J.; Lamoureux, F.; Wils, J. CYP2C19 Pharmacogenetics and Clopidogrel Prescription in a University Hospital: A Descriptive Study in a Clinical Data Warehouse. Preprints2023, 2023090730. https://doi.org/10.20944/preprints202309.0730.v1
Maes, A.; Gosselin, L.; Triquenot, A.; Darmoni, S.; Grosjean, J.; Lamoureux, F.; Wils, J. CYP2C19 Pharmacogenetics and Clopidogrel Prescription in a University Hospital: A Descriptive Study in a Clinical Data Warehouse. Preprints 2023, 2023090730. https://doi.org/10.20944/preprints202309.0730.v1
Maes, A.; Gosselin, L.; Triquenot, A.; Darmoni, S.; Grosjean, J.; Lamoureux, F.; Wils, J. CYP2C19 Pharmacogenetics and Clopidogrel Prescription in a University Hospital: A Descriptive Study in a Clinical Data Warehouse. Preprints2023, 2023090730. https://doi.org/10.20944/preprints202309.0730.v1
APA Style
Maes, A., Gosselin, L., Triquenot, A., Darmoni, S., Grosjean, J., Lamoureux, F., & Wils, J. (2023). CYP2C19 Pharmacogenetics and Clopidogrel Prescription in a University Hospital: A Descriptive Study in a Clinical Data Warehouse. Preprints. https://doi.org/10.20944/preprints202309.0730.v1
Chicago/Turabian Style
Maes, A., Fabien Lamoureux and Julien Wils. 2023 "CYP2C19 Pharmacogenetics and Clopidogrel Prescription in a University Hospital: A Descriptive Study in a Clinical Data Warehouse" Preprints. https://doi.org/10.20944/preprints202309.0730.v1
Abstract
Clopidogrel is one of the most prescribed antiplatelet drugs for cardiovascular diseases prevention. Clopidogrel is a prodrug metabolised by CYP2C19 in active metabolites with anti-aggregant effect. Pharmacogenetic variants such as CYP2C19*2 variant can alter the anti-aggregant effect of clopidogrel leading to a higher risk of cardiovascular disease relapse. The aim of this study was to evaluate the prescription characteristics of CYP2C19 pharmacogenetics in patients on clopidogrel treatment, based on a specific query in a clinical data warehouse. We evaluated the demographics of patients, prescribers, medical indications, CYP2C19 pharmacogenetic tests and therapeutic changes. Neurologists were the main prescribers of CYP2C19 pharmacogenetic tests associated with clopidogrel treatment in a context of suspicion of stroke relapse. Pharmacogenetic tests were mainly prescribed a posteriori to clopidogrel prescription. Clopidogrel pharmacogenetic resistance was associated with the prescription of lysine acetylsalicylate in substitution of clopidogrel. Clear clinical practice guidelines are needed to position CYP2C19 pharmacogenetic testing for patients on clopidogrel treatment.
Keywords
clopidogrel; pharmacogenetics; cytochrome P-450 CYP2C19; Clinical Data Warehouse; personalized medicine
Subject
Biology and Life Sciences, Other
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
